# Estuary Biotherapeutics

**Source:** https://www.startuphub.ai/startups/estuary-biotherapeutics
**Profile type:** Startup

> Biotechnology company developing genetic medicines for patients with serious kidney diseases, focusing on autosomal dominant polycystic kidney disease (ADPKD).

## About

Estuary Biotherapeutics is a biotechnology company focused on developing genetic medicines for patients with serious kidney diseases. Their lead programs, EST-201 and EST-101, are gene therapies targeting the root cause of autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease. The company aims to bring these therapies into clinical trials to transform the course of the disease for patients.

## Key facts

- **Slug:** estuary-biotherapeutics
- **Website:** https://estuarybio.com
- **Location:** Menlo Park, United States
- **Founded:** 2022-01-01
- **Operating status:** Active
- **Total funding:** $93M
- **Sectors / tags:** Biotechnology, Biotech, MedTech, Genomics, Drug Discovery

## StartupHub.ai scores

- **Agent Readiness:** D (43/100)
- **Site Speed:** 84/100
- **Data Trust:** 61/100

## Funding rounds

| Date | Round | Amount | Lead investors |
| --- | --- | --- | --- |
| 15 Oct 2026 | [Series A](https://www.startuphub.ai/investment_rounds/estuary-biotherapeutics-series-a-2026) | $93M | [RA Capital](https://www.startuphub.ai/investors/ra-capital) |

## Tech stack

Detected on estuarybio.com, last scanned 2026-10-16.

- **Frontend:** Next.js
- **Analytics:** Google Analytics 4
- **CDN:** Vercel
- **Email provider:** Google Workspace

## JSON-LD

Structured data aligned with this page's `<script type="application/ld+json">` (included when the profile is server-rendered).

```json
{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.startuphub.ai"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Startups",
          "item": "https://www.startuphub.ai/startups"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Estuary Biotherapeutics",
          "item": "https://www.startuphub.ai/startups/estuary-biotherapeutics"
        }
      ]
    },
    {
      "@type": "ProfilePage",
      "@id": "https://www.startuphub.ai/startups/estuary-biotherapeutics#webpage",
      "url": "https://www.startuphub.ai/startups/estuary-biotherapeutics",
      "name": "Estuary Biotherapeutics - AI Startup Profile | StartupHub.ai",
      "description": "This is the StartupHub.ai profile of Estuary Biotherapeutics. Estuary Biotherapeutics is a startup founded in 2022, operating in Biotechnology and Biotech. Biotechnology company developing genetic medicines for patients with serious kidney diseases, focusing on autosomal dominant polycystic kidney disease (ADPKD). Headquartered in Menlo Park, United States.",
      "dateModified": "2026-10-16T11:50:05.523Z",
      "mainEntity": {
        "@type": "Organization",
        "@id": "https://www.startuphub.ai/startups/estuary-biotherapeutics#organization"
      }
    },
    {
      "@type": "Organization",
      "@id": "https://www.startuphub.ai/startups/estuary-biotherapeutics#organization",
      "name": "Estuary Biotherapeutics",
      "url": "https://estuarybio.com",
      "logo": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/e9290c86-4fa2-404f-9ac5-a54c77643e06-square.webp",
      "image": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/e9290c86-4fa2-404f-9ac5-a54c77643e06-square.webp",
      "description": "Estuary Biotherapeutics is a biotechnology company focused on developing genetic medicines for patients with serious kidney diseases. Their lead programs, EST-201 and EST-101, are gene therapies targeting the root cause of autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease. The company aims to bring these therapies into clinical trials to transform the course of the disease for patients.",
      "foundingDate": "2022-01-01",
      "address": {
        "@type": "PostalAddress",
        "addressLocality": "Menlo Park",
        "addressCountry": "US"
      },
      "knowsAbout": [
        "Biotechnology",
        "Biotech",
        "MedTech",
        "Genomics",
        "Drug Discovery"
      ]
    }
  ]
}
```